Immunophenotypically varied cell subpopulations in primary and metastatic human melanomas. Monoclonal antibodies for diagnosis, detection of neoplastic progression and receptor directed immunotherapy

Anticancer Research

Volumn 16, Issue 1, 1996, Pages 517-532

  Bodey, Bela ^a,e   Kaiser, Hans E ^b,c   Goldfarb, Ronald H ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Diagnosis; Human; Immunocytochemistry; Integrins; Melanoma; Metastatic; Monoclonal antibodies; Neoplastic progression; p53; Primary; Receptor directed immunotherapy; Tumor suppressor genes

Indexed keywords

ACTIN; ALKALINE PHOSPHATASE; BIOTIN; CARCINOEMBRYONIC ANTIGEN; CD8 ANTIGEN; CYTOKERATIN; HLA ANTIGEN CLASS 1; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; HMB 45 ANTIGEN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN P53; PROTEIN S 100; STREPTAVIDIN; UNCLASSIFIED DRUG; VIMENTIN;

ANTIGEN DETECTION; ARTICLE; CANCER GROWTH; CELL SUBPOPULATION; CLINICAL ARTICLE; CYTOLYSIS; CYTOSKELETON; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INTERMEDIATE FILAMENT; MELANOMA; MELANOMA CELL; METASTASIS; METASTASIS POTENTIAL; ONCOGENE C ERB; ONCOGENE C MYC; ONCOGENE NEU; PRIORITY JOURNAL; SCREENING; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE PROGRESSION; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; MELANOMA; MICE; P-GLYCOPROTEIN; S100 PROTEINS; SKIN NEOPLASMS;

EID: 0029872467     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (152)

1. Darlington DC: The plasmagene theory of the origin of cancer. Brit J Cancer 2: 118-126, 1948.
2. Pitot HC, Grosso L and Dunn T: The role of the cellular genome in the stages of carcinogcnesis. In: Genes and Cancer, Proc. of a Cetus-UCLA Symposium, held in Steamboat Springs, Colorado. March 11-17, 184, eds. JM Bishop, JD Rowley and M Greaves, Alan R Liss Inc, New York, pp. 81-98, 1984.
3. Foulds L. Tumour progression and neoplastic development. In: Cellular Control Mechanism and Cancer, eds. Muhlbock O, Emmelot P, Elsevier Press, Amsterdam, p. 242, 1964
4. Kelly K, Siebenlist U: The regulation and expression of c-myc in normal and malignant cells. Ann Rev Immunol 4: 317-338, 1986.
5. Legha SS: Current therapy for malignant melanoma. Seminars in Oncol 16: 34-44, 1989.
6. Fountain JW, Bale SJ, Housman DE, Dracopoli NC: Genetics of Melanoma. Cancer Surveys 9: 645-671, 1990.
7. Greene MH, Fraumeni JF, Jr: The hereditary variant of malignant melanoma. In. Clark WH, Jr, Goldman LI and Mastrangelo MJ eds., Human Malignant Melanoma. Grune & Stratton, New York, pp. 139-166, 1979.
8. Wallace DB, Beardmore GL, Exton LA: Familial malignant melanoma. Annals Surgery 177: 15-20, 1973.
9. Duggleby WF, Stoll H, Priore RL, Greenwald P, Graham S: A genetic analysis of melanoma-polygenic inheritance as a threshold trait. Am J Epidem 114: 63-72, 1981
10. Clark WM Jr, Reimer RR, Green M, Ainsworth AM, Mastrangelo MJ: The atypical mole syndrome. Arch Dermatol 114: 732-737, 1978.
11. Newton JA: Diagnosis and Management of Melanoma in Clinical Practice. Eds. Kirklam N, Cotton DWK, Mallemand R, White JE, Rosin D, Springer-Verlag, Berlin, pp. 53-60, 1992.
12. Clark NH, From L, Bernadino EA, Mihm MC: The histogenesis and biological behaviour of primary human malignant melanoma of the skin Cancer Res 29: 705-726, 1992.
13. Clark WH Jr, Elder DE, Guerry D, Epstein ME, Greene MH, van Horn M: A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Human Pathol 15: 1147-1165, 1984.
14. Poste G. Pathogenesis of metastatic disease: Implications for current therapy and for the development of new therapeutic strategies. Cancer Treat Rep 70: 183-198, 1986.
15. Duray PH, Palazzo J, Gown AM, Ohuchi N: Melanoma cell heterogeneity. Cancer 61: 2460-2468, 1988.
16. Jimbow K, Salopek T: Chemical and immunohistochemical properties of dysplastic nevi compared to malignant melanoma. Abstract. Melanoma Res 3: 19, (Suppl. 1), 1993.
17. De Luca M, D' Anna F, Bondanza S, Franzi AT, Cancedda R: Human epithelial cells induce human melanocytic growth in vitro but only skin keratinocytes regulate its proper differentiation in the absence of dermis. J. Cell Biol 107: 1919-1926, 1988.
18. Wollina U, Kilian U, Henkel U, Schaarschmidt HY, Knopf B: The initial steps of tumor progression in melanocytic lineage: A histochemical approach. Anticancer Res 11: 1405-1414, 1991.
19. Guerry D, Synnestvedt M, Elder DE, Schultz D: Lessons from tumor progression. The invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol 100: S342-345, 1993.
20. Herlyn M, Clark WH, Rodeck U, Mancianti ML, Jambrosic J, Koprowski H: Biology of tumor progression in human melanocytes. Lab Invest 56: 461-474, 1987.
21. Fearon ER, Vogelstein B: A genetic model for colorectal carcinogenesis. Cell 61: 759-767, 1990.
22. Kerbel RS: Expression of multi-cytokine resistance and multigrowth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm. Am J Pathol 141: 519-524, 1992.
23. Lu C, Kerbel RS: Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 120: 1281-1288, 1993.
24. Weterman MAJ, van Muijen GNP, Bloemers HPJ, Ruiter DJ: Biology of Disease. Molecular markers of melanocytic tumor progression. Lab Invest 70: 593-608, 1994.
25. Ullrich A, Schlessinger J Signal transduction by receptors with tyrosine kinase activity. Cell 61. 203-212, 1990.
26. Wynford-Thomas D: Oncogenes and anti-oncogenes; the molecular basis of tumour behaviour. J Pathol 165. 187-201, 1991.
27. Schlessinger J. Ullrich A: Growth factor signaling by receptor tyrosine kinases. Neuron 9. 383-391, 1992.
28. Tabin CJ, Bradley SM, Bargmann CI, Weinberg RA: Papageorge AG, Scolnick EM, Dhar R, Lowy DR, Chang EH: Mechanisms of activation of a human oncogene. Nature 300: 143-149, 1982.
29. Knudson AG, Jr: Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 45: 1437-1443, 1985
30. Graf T, Beug H: Avian leukemia viruses: interaction with their target cells in vivo and in vitro Biochim Biophys Acta 516: 269-299, 1978.
31. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K: Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 319: 230-234, 1986.
32. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A, Schlessinger J, Waterfield MD: Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307: 521-527, 1983.
33. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J: Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 80: 1337-1341, 1983.
34. Semba K, Kamata N, Toyoshima K, Yamamoto T: A v-erbB-related protooncogene, c-erbB-2 is distinct from the c-erb-1 epidermal growth factor receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82: 6497-6501, 1985.
35. van Zoelen EJJ, van Rooijen MA, van Oostwaard TMJ, de Laat SW: Production of transforming growth factors by Simian sarcoma virus-transformed cells. Cancer Res 47: 1582-1587, 1987.
36. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6: 3341-3351, 1987.
37. Bargmann CI, Weinberg RA: Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J 7: 2043-2052, 1988.
38. Bargmann CI, Hung M-C, Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319: 226-230, 1986.
39. erbB2. Science 249: 1552-1555, 1990.
40. King CR, Borrello I, Bellot F, Comoglio P, Schlessinger J: EGF binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. EMBO J 7:1647-1651, 1988.
41. neu: A potential model for receptor interactions. EMBO J 7: 995-1001, 1988.
42. Kraus MH, Popescu NC, Amsbaugh SC, King CR: Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 6: 605-610, 1987.
43. Slamon DJ, Clark GM, Wong SG, Levin WL, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177-182, 1987.
44. van de Vijver M, van de Bersselaar R, Devilee P, Cornelisse C, Peterse J, Nusse R: Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell. Biology 7: 2019-2023, 1987.
45. Slamon DJ: Protooncogenes and human cancers. N Engl J Med 317: 955-957, 1987.
46. Hayman MJ, Ramsay GM, Savin K, Kitchener G, Graf T, Beug H: Identification and characterization of the avian erythroblastosis virus erbB gene product as a membrane glycoprotein. Cell 32: 579-588, 1983.
47. Hayman MJ, Beug H: Identification of a form of the avian erythroblastosis virus erbB gene product at the cell surface Nature 309: 460-462, 1984.
48. Elder DE, Rodeck U, Thurin J, Cardillo F, Clark WH, Stewart R, Herlyn M: Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer Res 49: 5091-5096, 1989.
49. Rodeck U, Herlyn M: Growth factors in melanoma. Cancer Metast Rev 20: 89-101, 1991.
50. De Wit PEJ, Moretti S, Koenders PG, Weterman MAJ, van Muijen GNP, Gianotti B, Ruiter DJ: Increasing epidermal growth factor receptor expression in human melanocytic tumor progression. J Invest Dermat 99: 168-173, 1992.
51. Rodeck U: Growth factor independence and growth regulatory pathways in human melanoma development. Cancer Metast Rev 12: 219-226, 1993.
52. Bister K, Duesberg PH: Genetic structure and transforming genes of avian retroviruses. In: Advances in Viral Oncology, Klein G. (ed.). 1: 3-42. New York: Raven, 1982.
53. Sinkovics JG: Oncogenes and growth factors. CRC Critical Rev. Immunol 8. 217-298, 1988.
54. Bishop JM: Oncogenes. Scientific American 246: 80-90, 1982.
55. Battey J, Moulding C, Taub R, Murphy W, Stewart T, Potter H, Lenoir G, Leder P: The human c-myc oncogene: Structural consequences of translocation into the IgH locus in Burkitt Lymphoma. Cell 34: 779-787, 1983.
56. Bernard O, Cory S, Gerondakis S, Webb E, Adams JM: Sequence of the murine and human cellular myc oncogenes and two modes of myc transcription resulting from chromosome translocation in B lymphoid tumors. EMBO J 2: 2375-2383, 1983.
57. Shih CK, Linial M, Goodenow MM, Hayward WS: Nucleotide sequence 5′ of the chicken c-myc coding region: Localization of a noncoding exon that is absent from myc transcripts in most avian leukosis virus-induced lymphomas. Proc Natl Acad Sci USA 81: 4697-4701, 1984.
58. Kelly K, Siebenlist U: The role of c-myc in the proliferation of normal and neoplastic cells. J Clin Immunol 5: 65-77, 1985.
59. Kohl NE, Legouy E, DePinho RA, Nisen PD, Smith RK, Gee CE, Alt FW: Human N-myc is closely related in organization and nucleotide sequence to c-myc. Nature 319: 73-77, 1986.
60. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL: The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533-538, 1986.
61. Langdon WY, Harris AW, Cory S, Adams JM: The c-myc oncogene perturbs B lymphocyte development in Eu-myc transfected mice. Cell 47: 11-18, 1986.
62. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day III RS, Johnson BE, Skotnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1994.
63. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991.
64. Stretch JR, Gatter KC, Ralfkiaer E, Lane DP, Harris AL: Expression of mutant p53 in melanoma. Cancer Res 51: 5976-5979, 1991.
65. Volkenandt M, Schlegel U, Nanus DM, Albino AP: Mutational analysis of the human p53 gene in malignant melanoma. Pigment Cell Res 4: 35-40, 1991.
66. Akslen LA, Morkve O: Expression of p53 protein in cutaneous melanoma. Int J Cancer 52: 13-16, 1992.
67. Koshland DE, Jr: Molecule of the year. Editorial Science 202: 1953, 1993.
68. Wynford-Thomas D: p53 in tumour pathology: can we trust immunohistochemistry? J Pathol 166: 320-330, 1992.
69. Lassam NJ, From L, Kahn HJ: Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 53: 2235-2238, 1993.
70. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, Sobel ME: Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 80: 200-205, 1988.
71. Leone A, Flatow U, King CR, Sandeen MA, Margulies IMK, Liotta LA, Steeg PS: Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell 65: 25-35, 1991.
72. Hailat N, Keim DR, Melhem RF, Zhu X, Eckerskorn C, Brodeur GM, Reynolds CP, Seeger RC, Lottspeich F, Strabler JR, Hanash SM: High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc amplification. J Clin Invest 88: 341-345, 1991.
73. Florenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS, Fodstad O: Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression. Cancer Res 52: 6088-6091, 1992.
74. Suter L, Brueggen J, Broecker EB, Sorg C: A tumor-associated antigen expressed in melanoma cells with lower malignant potential. Int J Cancer 35: 789-791, 1985.
75. Albino AP, Sozzi G, Nanus DM, Jhanwar SC, Houghton AN: Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. Oncogene 7: 2315-2321, 1992.
76. Morrison ME, Vijayasaradhi S, Engelstein D, Albino AP, Houghton AN: A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med 777: 1135-1143, 1993.
77. Atkinson B, Ernst CS, Ghrist BFD, Ross AH, Clark WH, Herlyn M, Herlyn D, Maul G, Steplewski Z, Koprowski H: Monoclonal antibody to a highly glycosylated protein reacts in fixed tissue with melanoma and other tumors. Hybridoma 4: 243-255, 1985.
78. Hotta H, Ross AH, Huebner K, Isobe M, Wendeborn S, Chao MV, Ricciardi RP, Tsujimoto Y, Croce CM, Koprowski H: Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression. Cancer Res 48: 2955-2962, 1988.
79. Demetrick DJ, Herlyn D, Tretiak M, Creasey D, Clevers H, Donoso LA, Vennegoor CJ, Dixon WT, Jerry LM: ME491 melanoma-associated glycoprotein &mily: antigenic identity of ME491, NK/C3, Neuroglandular Antigen (NGA), and CD63 proteins. J Natl Cancer Inst 84: 422-429, 1992.
80. Kondoh M, Ueda M, Ichihashi M, Mishima Y: Decreased expression of human melanoma-associated ME491 along the progression of melanoma precanceroses to invasive and metastatic melanomas. Melanoma Res 3: 241-245, 1993.
81. Si ZY, Hersey P: Expression of the neuroglandular antigen and analogues in melanoma- CD9 expression appears inversely related to metastatic potential of melanoma. Int J Cancer 54: 37-43, 1993.
82. van der Bruggen P, Traversari C, Chomez P, Lurquin C, de Plaen E, van den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic lymphocytes on a human melanoma. Science 254: 1643-1647, 1991.
83. Rimoldi D, Romero P, Carrel S: The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas. Int J Cancer 54: 527-528, 1993.
84. Bergman W, Ruiteri DJ, Scheffer E, van Vloten WA: Melanocytic atypia in dysplastic nevi: immunohistochemical and cytophotometrical analysis. Cancer 61: 1660-1666, 1988.
85. Versteeg R, Noordermeer IA, Kruese-Wolters M, Ruiter DJ, Schrier PI: c-myc down-regulates class I HLA expression in human melanomas. EMBO J 7: 1023-1029, 1988.
86. Ruiter DJ, Mattijsen V, Broecker E-B, Ferrone S: MHC antigens in human melanomas. Semin. Cancer Biol 2: 35-45, 1991
87. Fink-Puches R, Smolle J: Cytoskeleton and motility: an immunohistological and computer simulation analysis of melanocytic skin tumors. J Cutaneous Pathol 20: 130-136, 1993.
88. Byers HR, Etoh T, Doherty JR, Sober AJ, Mihm MC Jr: Cell migration and actin organization in cultured human primary, reccurent cutaneous and metastatic melanoma. Time-lapse and image analysis. Am J Pathol 139: 423-435, 1991.
89. Sadano H, Inoue M, Taniguchi S: Differential expression of vinculin between weakly and highly metastatic B16-melanoma cell lines. Jpn J Cancer Res 83: 625-630, 1992.
90. Hay ED: Theory for epithelial-mesenchymal transformation based on the "fixed cortex" cell morality model. Cell Motil Cytoskeleton 14: 455-457, 1989.
91. Knapp AC, Franke WW: Spontaneous losses of control of cytokeratin gene expression in transformed, non-epithelial human cells occurring at different levels of regulation. Cell 59: 67-79, 1989.
92. Miettinen M, Franssila K: Immunohistochemical spectrum of malignant melanoma: the common presence of keratins. Lab Invest 61: 623-628, 1989.
93. Hendrix MJC, Seftor EA, Chu YW, Seftor REB, Nagle RB, McDaniel KM, Leong SP, Yohem KH, Leibovitz AM, Meyskens FL, Jr: Coexpression of vimentin and keratins by human melanoma tumor cells: correlation with invasive and metastatic potential. J Natl Cancer Inst 84: 165-174, 1992.
94. Chu YW, Oshima RG, Hendrix MJ: Expression of keratins 8 and 18 in mouse L cells results in an increase in migratory and invasive ability. J Cell Biol 111: 42A, 1990.
95. Zarbo RJ, Gown AM, Nagle RB, Visscher DW, Crissman JD: Anomalous cytokeratin expression in malignant melanoma: one-and two-dimensional western blot analysis and immunohistochemical survey of 100 melanomas. Modern Pathol 3: 494-501, 1990.
96. Farmilo AJ, Stead RH: Fixation in immunocytochemistry. In: Handbook Immunochemical Staining Methods, Ed. Naish SJ, DAKO Corporation pp. 24-29, 1989.
97. Fernando SS, Johnson S, Bate J: Immunohistochemical analysis of cutaneous malignant melanoma: comparison of S-100 protein, HMB-45 monoclonal antibody and NKI/C3 monoclonal antibody. Pathology 26: 16-19, 1994.
98. Smoller BR, McNutt NS, Hsu A: HMB-45 recognizes stimulated melanocytes. J Cutan Pathol 16: 49-53, 1989.
99. Moore BW: A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 19: 739-744, 1965.
100. Stosiek P, Kasper M, Karsten U: Expression of cytokeratin 19 during human liver organogenesis. Liver 10: 59-63, 1990.
101. van Eyken P, Sciot R, Callea F, Ramaekers F, Schaart G, Desmet VJ: A cytokeratin immunohistochemical study of hepatoblastoma. Human Pathol 27: 302-308, 1990.
102. Leader M, Collins M, Makin C, Henry K. Vimentin: an evaluation of its role as a tumour marker. Histopathology 11: 63-72, 1987
103. Shi S-R, Key ME, Kalra KL: Antigen retrieval in formalin fixed, paraffinembedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741-748, 1991.
104. Shi S-R, Cote C, Kalra KL, Taylor CR, Tandon AK: A technique for retrieving antigens in formalin-fixed, routinely acid-decalcified, celloidin-embedded human temporal bone sections for immunohistochemistry. J Histochem Cytochem 40: 787-792, 1992.
105. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques, a comparison of ABC and unlabeled antibody (PAP) procedure. J Histochem Cytochem 29: 577-581, 1981.
106. Janckila AJ, Yam LT, Li C-Y: Immunoalkaline phosphatase cytochemistry. Amer J Clin Pathol 84: 476-480, 1985.
107. Bodey B, Zeltzer PM, Saldivar V, Kemshead J: Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies. Int J Cancer 45: 1079-1087, 1990.
108. Yam LT, Janckila AJ, Epremian BE, Li C-Y: Diagnostic significance of levamisole-resistant alkaline phosphatase in cytochemistry and immunocytochemistry. Amer J Clin Pathol 91: 31-36, 1989.
109. Strasburger CJ, Amir-Zaltsman Y, Kohen F: The avidin-biotin reaction as an universal amplification system in immunoassays. Prog Clin Biol Res 285: 79-100, 1988.
110. Wilchek M, Bayer EA: Introduction to avidin-biotin technology. Methods Enzymol 184: 5-13, 1990.
111. Duhamel RC, Whitehead JS: Prevention of nonspecific binding of avidin. Methods Enzymol 184: 201-207, 1990.
112. Diamandis EP, Christopoulos TK: The biotin-(strept)avidin system: principles and applications in biotechnology. Clin Chem 37: 625-636, 1991.
113. Bodey B, Cosgrove M, Gonzalez-Gomez I, Siegel SE, Martin SE, Gilles FH: Coexpression of four intermediate filament subclasses in childhood glial neoplasms. Modern Pathol 4: 742-749, 1991.
114. Gottschalk J, Jautzke G, Schreiner C: Epithelial and melanoma antigens in gliosarcoma. An immunohistochemical study. Pathol Res Pract 188: 182-190, 1992.
115. Om A, Ghose T, Rowden G: Keratin and carcinoembryonic antigen (CEA) in human melanoma cells. Virchows Arch B[Cell Pathol] 61: 81-87, 1991.
116. Murphy JK: Carcinoembryonic antigen expression in malignant melanoma. J Pathol 169: 182a, 1993.
117. Sanders DSA, Evans AT, Allen CA, Bryant FJ, Johnson GD, Hopkins J, Stocks SC, Marsden JR, Kerr MA: Classification of CEA-related positivity in primary and metastatic malignant melanoma. J Pathol 772: 343-348, 1994.
118. Johnson JP, Stade BG, Holtzmann B, Schwable W, Reitmuller G: De novo expression of ICAM-1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci USA 86: 641-644, 1989.
119. Denton KJ, Stretch JR, Gatter KC, Harris AL: A study of adhesion molecules as markers of progression in malignant melanomas. J Pathol 167: 187-191, 1992.
120. Hostetter RB, Cambell DE, Chi KF, Kerckhoff S, Cleary KR, Ullrich S, Thomas P, Jessup JM: Carcinoembryonic antigen enhances the metastatic potential of human colorectal carcinoma. Arch Surg 125: 300-304, 1990.
121. Lehmann JM, Rithmuller G, Johnson P: MUC18, a market of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc. Natl Acad Sci USA 86: 9891-9895, 1989.
122. Albelda SM, Buck CA: Integrins and other cell adhesions molecules. FASEB J 4: 2868-2880, 1990.
123. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowsky S, Hemler ME, Lobb RR: VCAM-1 on activated endothelium interacts with the leucocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60: 577-581, 1990.
124. Jonjic N, Martinpadura I, Pollicino T, Bernasconi S, Jilek P, Bigotti A, Mortarini R, Anichini A, Parmiani G, Colotta F, Dejana E, Mantovani A, Natali PG: Regulated expression of Vascular Cell Adhesion Molecule-1 in human malignant melanoma. Am J Pathol 141: 1323-1330, 1992.
125. Holzmann B, Johnson JP, Kaudewitz P, Riethmuller G: In situ analysis of antigens on malignant and benign cells of the melanocyte lineage. J Exp Med 161: 366-377, 1985
126. Anichini A, Mortarini R, Supino R, Parmiani G: Human melanoma cells with high susceptibility to cell-mediated lysis can be identified on the basis of ICAM-1 phenotype. VLA profile and invasive ability Int J Cancer 46: 508-515, 1990.
127. Giavazzi R, Chirivi RGS, Garofalo A, Rambaldi A, Hemingway I, Pigott R, Gearing AJH: Soluble intercellular adhesion molecule 1 is released by human melanoma cells and is associated with tumor growth in nude mice. Cancer Res 52: 2628-2630, 1992.
128. Wang Z, Cao Y, D'Urso CM, Ferrone S: Differential susceptibility of cultured human melanoma cell lines to enhancement by retinoic acid of intercellular adhesion molecule 1 expression. Cancer Res 52: 4766-4772, 1992.
129. Kirnbauer R, Charvat B, Schauer E, Kock A, Urbanski A, Forster E, Neuner P, Assmann I, Luger TA, Schwarz T: Modulation of intercellular adhesion molecule 1 expression on human melanocytes and melanoma cells: evidence for a regulatory role of IL-6, IL-7, TNF-beta, and UVB light. J Invest Dermatol 98: 320-326, 1992.
130. Scheibenbogen C, Keilholz U, Meuer S, Dengler T, Tilgen W, Hunstein W: Differential expression and release of LFA-3 and ICAM-1 in human melanoma cell lines. Int J Cancer 54: 494-498, 1993.
131. Altomonte M, Gloghini A, Bertola G, Gasparollo A, Carbone A, Ferrone S, Maio M: Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res 53: 3343-3348, 1993.
132. Schadendorf D, Gawlik C, Haney U, Ostmeier H, Suter L, Czarnetzki B.M. Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours. J. Pathol 170: 429-434, 1993
133. Danen EHJ, van Muijen GNP, van de Wiel van Kemenade E, Jansen KFJ, Ruiter DJ, Figdor CG: Regulation of integrin-mediated adhesion to laminin and collagen in human melanocytes and in non-metastatic and highly metastatic human melanoma cells. Int J Cancer 54: 315-321, 1993.
134. Vink J, Thomas L, Eton T, Bruijn JA, Mihm MC, Gattoni-Celli S, Byers HR: Role of beta-1 integrins in organ specific adhesion of melanoma cells in vitro. Lab Invest 68: 192-203, 1993.
135. Mortarini R, Anichini A: From adhesion to signalling: roles of integrins in the biology of melanoma. Melanoma Res 3: 87-97, 1993.
136. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M, Buck CA: Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res 50: 6757-6764, 1990.
137. Gehlsen KR, Davis GE, Sriramarao P: Integrin expression in human melanoma cells with differing invasive and metastatic properties. Clin. Exp. Metastasis 10: 111-120, 1992.
138. Danen EHJ, ten Berge PJM, van Muljen GNP, van'tHof-Grootenboer AE, Broecker EB, Ruiter DJ: Emergence of alpha-5-beta-1 fibronectin- and alpha-vbeta-3 vitronectin receptor expression in melanocytic tumor progression Histopathol 24: 249-256, 1994.
139. Natali PG, Nicotra MR, Bartolazzi A, Cavaliere R, Bigotti A Integrin expression in cutaneous malignant melanoma: association of the alpha-3/beta-1 heterodimer with tumor progression. Int J Cancer 54: 68-72, 1993
140. Seftor REB, Seftor EA, Stetler-Stevenson WG, Hendrix MJC: The 72 kDa typeIV collagenase is modulated via differential expression of alpha-v-beta-3 integrin and alpha-5-beta-1 integrin during human melanoma cell invasion. Cancer Res 53: 3411-3415, 1993.
141. Liotta LA: Tumour invasion and metastases: role of the extracellular matrix. Cancer Res 46: 1-7, 1986.
142. Newell PS: The clonal evolution of tumor cell subpopulations. Science 194: 23-28, 1976.
143. Marx JL: Tumours, a mixed bag of cells. Science 215: 275-277, 1982.
144. Cifone MA, Fidler IJ: Increasing metastatic potencial IS associated with increasing genetic instability of clones isolated from murine neoplasms. Proc Natl Acad Sci USA 78: 6949-6952, 1982.
145. McDonald JA: Matrix regulation of cell shape and gene expression. Curr. Opin. Cell Biol 1: 995-999, 1989.
146. van Dumen CM, Fleuren GJ, Bruijn JA: The extracellular matrix in pigmented skin lesions: an immunohistochemical study. Histopathol 24: 33-40, 1994.
147. Faassen AE, Mooradian DL, Tranquillo RT, Dickinson RB, Letourneau PC, Oegema TR, McCarthy JB: Cell surface CD44-related chondroitin sulfate proteoglycan is required for transforming growth factor-beta-stimulated mouse melanoma cell motility and invasive behavior on type-1 collagen J Cell Sci 105: 501-511, 1993.
148. Kohn EC, Hollister GH, Dipersio JD, Wahl S, Liotta LA, Schiffmann E: Granulocyte-Macrophage Colony-Stimulating Factor induces human melanoma-cell migration Int J Cancer 53: 968-972, 1993.
149. Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1032: 89-118, 1990.
150. Halaban R, Kwon BS, Ghosh S, Bovi PD, Baird A: bFGF as an autocrine factor for human melanomas. Oncogene Res 3: 177-186, 1988.
151. Becker D, Lee PL, Rodeck U, Herlyn M: Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in melanocytes and malignant melanomas leads to inhibition of proliferation and sign indicative of differentiation. Oncogene 7: 2303-2313, 1992.
152. Shih IM, Herlyn M: Role of growth factors and their receptors in the development and progression of melanomas. J Invest Dermatol 100: S196-S203, 1993